MRD testing detects residual myeloma after treatment, offering valuable insights into disease status. Negative MRD results indicate minimal myeloma presence, providing reassurance and delaying the need for treatment. Positive MRD results suggest lingering myeloma requiring closer monitoring and potential therapy adjustments. MRD testing's main utility lies in clinical trials, where it can differentiate treatment efficacy and inform trial endpoints.
The BOTTOM LINE: MRD testing holds significant value in myeloma management, offering insights beyond traditional remission assessments. However, standardization is needed, and FDA approval for clinical use is awaited, promising advancements in treatment strategies.
If you have a question that you’d like to suggest for a future episode of Ask Dr. Durie, please submit it to [email protected].
Please note that Ask Dr. Durie is designed to address myeloma questions of the broadest possible audience interest. If you have a question of a personal nature, please contact our InfoLine Coordinators at 800.452.2873 or [email protected] (Please do not send email attachments or lab reports.).
This week's "Ask Dr. Durie" comes from a patient who wants to know about how valuable is MRD testing? Testing for minimal residual disease. And the answer is that this is quite important. Testing minimal residual disease is where you check to see if a small amount of myeloma is remaining in a bone marrow sample.
This can be by checking 100,000 cells where the sensitivity is called ten-to-the-minus-five or checking a million cells where the sensitivity would be ten-to-the-minus-six. And so, the value of this test is that if it's negative ten-to-the-minus-five or ten-to-the-minus-six, this means that there really is a very, very low level of myeloma in the body.
And this, is much better than just an assessment of a complete remission. And so, this is excellent news for a patient and can be very reassuring and certainly means that there's no immediate need for treatment. On the opposite side, if that type of MRD testing is positive, this means that there is definite residual myeloma in the bone marrow in the body and that this needs to be watched much more closely and that new therapy might actually be required.
Now, in the real world, setting the testing methods do still need some work, some standardization in terms of how they're collected, how they're processed and things like that. And so, one does need to be cautious right now until all of the standardization, in the real world, clinical setting is as well establish it. However, a main value for MRD testing is in clinical trials.
In clinical trials, if one treatment is being compared versus another in what's called a randomized trial, half the patients get one treatment and half get another. If more MRD occurs in one arm and one type of treatment. the amount, or the depth, then this means that one treatment is better than another. And so, this is obviously extremely helpful.
And that endpoint occurs much faster than waiting to see. How long does the remission last? And so we can do MRD testing after 9-to-12 months in patients where with these new therapies, remissions can last for five, six years or even longer. And so, this is a big advantage. What we're waiting for right now is to see if the FDA will indeed accept this approach.
To give what they would call accelerated approval based on achievement of this type of MRD negativity. And so, this is something that everyone is really hopeful about. So the BOTTOM LINE is: MRD testing is very useful, very useful. It needs to be standardized. And we are indeed waiting for the FDA to give its seal of approval so that it might be usable in the clinical trials setting.
Professor of Medicine, Hematologist/Oncologist, and Honoree MD at the University of Brussels, Dr. Brian G.M. Durie is a co-founder of the IMF and a member of the IMF Board of Directors.
